Sean D. Sullivan

Last updated
Professor
Sean D. Sullivan
Sullivan headshot - clean.png
Born (1960-09-30) September 30, 1960 (age 64)
San Jose, CA, USA
Citizenship United States of America
Academic background
Alma mater University of California Berkeley (Ph.D.)
University of Texas, Austin (MSc.)
Oregon State University College of Pharmacy (BSc.Pharm.)
Doctoral advisor Teh-wei Hu
Influences Pharmacoeconomics, Health Economics

Sean D. Sullivan (born 1960) is an American health economist, professor, Member of the National Academies of Sciences, Engineering, and Medicine, [1] [2] and Fellow of the American Association for the Advancement of Science (AAAS) [3] who has contributed to pharmacoeconomics, health technology assessment, decision sciences, drug pricing, value-based insurance design, and health coverage and reimbursement decisions.

Contents

Sullivan was dean of the University of Washington School of Pharmacy from 2014 to 2022 and past president of ISPOR.

Education

Sullivan received his Bachelors of Pharmacy from Oregon State University, College of Pharmacy in 1983, Masters of Science from the University of Texas, Austin in 1986, and his Doctor of Philosophy from the University of California Berkeley in 1992. [4] During his doctoral training, Sullivan was advised by Teh-wei Hu, a prominent health economist at the University of California Berkeley.[ citation needed ]

Career

During his doctoral training, Sullivan was an Affiliate Assistant Professor at the College of Professional Studies, University of California San Francisco and Visiting Instructor at the School of Pharmacy, University of the Pacific. After his doctoral training, Sullivan took a position as Assistant Professor at the Schools of Pharmacy and Public Health/Community Medicine, University of Washington eventually reaching the rank of Full Professor. Sullivan was the past Stergachis Family Endowed Professor and Director of The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Associate Dean of Research, Graduate Education and New Initiatives at University of Washington School of Pharmacy, and Dean and Chief Academic Officer at University of Washington School of Pharmacy. Sullivan is currently Full Professor at University of Washington School of Pharmacy and University of Washington School of Public Health, and Visiting Professor at London School of Economics and Political Science. [4]

Research

The Academy of Managed Care Pharmacy (AMCP) Dossier, a comprehensive document containing information about the effectiveness, safety, and economic impact of a pharmaceutical agent, is used by healthcare decision-makers to inform them on policies associated with formulary coverage and price negotiation. [5] Sullivan was instrumental in its development along with Dell Mather, Deborah Atherly, Linda Sturm and John Watkins. Drawing inspiration from the Australian guidelines for informing drug coverage by the Pharmaceutical Benefits Advisory Committee (PBAC), they developed the framework for managed care organizations to standardize their decision-making process to incorporate clinical and economic outcomes, which included product description, place in therapy, comparator products, therapy intervention framework, supporting clinical data, supporting pharmacoeconomic data, system impact assessments-costs-outcomes, overall assessment. [6] This led to the first AMCP Dossier Format version 1.0, which was published in October 2000. [7] [8] Since its inception, the AMCP Dossier for Formulary Submissions has been widely used by managed care organizations and formulary managers to inform them on healthcare decisions regarding formulary coverage and price negotiations. In recognition of his contributions, Sullivan was elected to the National Academy of Medicine in 2020. [9]

Sullivan and colleagues were one of the first to evaluate the effectiveness of value-based formulary design on large healthcare systems to identify high-value interventions that insurers would be willing to pay out. [10] [11] [12]

In 2022, President Biden signed into law the Inflation Reduction Act (Public Law 117-169), which gave Medicare (United States) the ability to directy negotiate with pharmaceutical manufactures for some of the costliest drugs on the Part B and D plans. Sullivan and colleagues wrote a series of papers discussing the impact of this law on pharmaceutical pricing. [13] [14] [15] [16] In particular, they identified the complexities with Medicare's decision on price negotiations and a offered transparent and systematic process to arrive at an initial price offering. [17] [18]

Awards and Recognition

Sullivan has been a member of the National Academy of Medicine since 2020 [19] and a fellow of the American Association for the Advancement of Science since 2022. [20] Sullivan was awarded the Outstanding Alumnus Award from Oregon State University in 2019, [21] the David Almquist Award from the Washington State Pharmacy Association in 2016, the Career Research Achievement Award from the American Pharmacists Association in 2015, and the Steven G. Avey Award from the Academy of Managed Care Pharmacy in 2014. [22]

References

  1. ↑ "UWSOP Dean Sean D. Sullivan Elected To NAM". University of Washington. 19 October 2020. Retrieved 26 August 2024.
  2. ↑ "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. 19 October 2020. Retrieved 27 August 2024.
  3. ↑ "Sullivan Named 2022 AAAS Fellow". University of Washington. 3 February 2024. Retrieved 26 August 2024.
  4. 1 2 "Sean D. Sullivan". University of Washington.
  5. ↑ Watkins, John B.; Sullivan, Sean D.; Sampsel, Elizabeth; Fullerton, D S "Pete"; Graff, Jennifer S.; Fry, Richard N.; Lee, Jeff; Tam, Iris M.; Avery, Steven G. (June 2020). "Evolution of the AMCP Format for Formulary Submissions". Journal of Managed Care & Specialty Pharmacy. 26 (6): 696-700. doi:10.18553/jmcp.2020.26.6.696. PMC   10391300 . PMID   32463780.
  6. ↑ Langley, Paul C.; Sullivan, Sean D. (1996). "Pharmacoeconomic evaluations: guidelines for drug purchasers". Am J Manag Care. 2 (6): 671-677. doi:10.18553/jmcp.2020.26.6.689. PMC   10394428 . PMID   32463775.
  7. ↑ Academy of Managed Care Pharmacy. "AMCP Format for Formulary Submissions". Academy of Managed Care Pharmacy. Retrieved 19 December 2024.
  8. ↑ Sullivan, Sean D.; Lyles, Alan; Luce, Bryan; Grigar, Joseph (July 2001). "AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations". Journal of Managed Care Pharmacy. 7 (4): 272-282. doi:10.18553/jmcp.2001.7.4.272.
  9. ↑ National Academy of Medicine. "National Academy of Medicine Elects 100 New Members".
  10. ↑ Sullivan, Sean D.; Yeung, Kai; Vogeler, Carol; Murphy, Chad O.; Danielson, Dan; Veenstra, David L.; Garrison, Louis P.; Burke, Wylie; Watkins, John B. (2015). "Design, Implementation, and First-Year Outcomes of a Value-Based Drug Formulary". J Manag Care Spec Pharm. 21 (4): 269–75. doi:10.18553/jmcp.2015.21.4.269. PMC   10398289 . PMID   25803760.
  11. ↑ Yeung, Kai; Basu, Anirban; Hansen, Ryan N.; Watkins, John B.; Sullivan, Sean D. (2017). "Impact of a Value-Based Formulary on Medication Utilization, Health Services Utilization, and Expenditures". Med Care. 55 (2): 191–198. doi:10.1097/MLR.0000000000000630. PMC   5233590 . PMID   27579915.
  12. ↑ Yeung, Kai; Cruz, Maricela; Tsiao, Emily; Watkins, John B.; Sullivan, Sean D. (2024). "Drug use and spending under a formulary informed by cost-effectiveness". J Manag Care Spec Pharm. 29 (11): 1175–1183. doi:10.18553/jmcp.2023.29.11.1175. PMC   10778804 . PMID   37889867.
  13. ↑ Sullivan, Sean D. (March 2023). "Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions". Value Health. 26 (3): 394-399. doi:10.1016/j.jval.2022.11.015. PMID   36503034.
  14. ↑ Hernandez, Inmaculada; Cousin, Emma M.; Wouters, Olivier J.; Gabriel, Nico; Cameron, Teresa; Sullivan, Sean D. (March 1, 2024). "Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness". J Manag Care Spec Pharm. 30 (3): 218-225. doi:10.18553/jmcp.2023.23277. PMC   10909583 . PMID   38088899.
  15. ↑ Sullivan, Sean D.; Wouters, Olivier J.; Cousin, Emma M.; Kirihennedige, Ayuri S.; Hernandez, Inmaculada (October 2024). "Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program". Value Health. 27 (10): 1348-1357. doi:10.1016/j.jval.2024.08.001. PMID   39154910.
  16. ↑ Hernandez, Inmaculada; Cousin, Emma M.; Wouters, Olivier J.; Gabriel, Nico; Cameron, Teresa; Sullivan, Sean D. (June 21, 2024). "Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives". J Manag Care Spec Pharm. 30 (8): 762-772. doi:10.18553/jmcp.2024.24153. PMC   11293770 . PMID   38905356.
  17. ↑ Sullivan, Sean D.; Wouters, Olivier J.; Cousin, Emma M.; Kirihennedige, Ayuri S.; Hernandez, Inmaculada (October 2024). "Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program". Value Health. 27 (10): 1348-1357. doi:10.1016/j.jval.2024.08.001. PMID   39154910.
  18. ↑ Hernandez, Inmaculada; Cousin, Emma M.; Wouters, Olivier J.; Gabriel, Nico; Cameron, Teresa; Sullivan, Sean D. (June 21, 2024). "Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives". J Manag Care Spec Pharm. 30 (8): 762-772. doi:10.18553/jmcp.2024.24153. PMC   11293770 . PMID   38905356.
  19. ↑ National Academy of Medicine. "National Academy of Medicine Elects 100 New Members".
  20. ↑ American Association for the Advancement of Science. "2022 AAAS Fellows".
  21. ↑ Oregon State University. "2019 Icons of Pharmacy & Outstanding Young Alumni".
  22. ↑ AMCP Foundation. "2014 Steven G. Avey Award Recipient".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.